NR3C2 and heart failure: The use of mineralocorticoid receptor antagonists (43.6% vs. 21.2%, p-value = 0.003) and loop diuretics (56.4% vs. 22.5%, p-value < 0.001) was significantly higher in the end-stage HCM group, suggesting a greater need for heart failure management.